A.R.S. § 32-1979.06: Human immunodeficiency virus prevention; preexposure prophylaxis; postexposure prophylaxis; definitions

A. In addition to the authority provided in section 32-1979.04, a pharmacist who is licensed pursuant to this chapter may initiate and dispense human immunodeficiency virus preexposure prophylaxis and postexposure prophylaxis pursuant to the statewide written protocol approved by the board.

B. Before initiating a preexposure prophylaxis, a pharmacist shall:

1. Conduct or obtain a clinical laboratory improvement amendments-waived human immunodeficiency virus test and confirm a negative test result.

2. Assess the patient for contraindications, drug interactions and clinical eligibility consistent with the current guidelines of the United States centers for disease control and prevention.

C. Before initiating a postexposure prophylaxis, a pharmacist shall:

1. Determine that the patient presents within seventy-two hours after a potential exposure to the human immunodeficiency virus.

2. Conduct or obtain a human immunodeficiency virus test if feasible under the statewide written protocol.

3. Assess the patient for contraindications, drug interactions and clinical eligibility consistent with the current guidelines of the United States centers for disease control and prevention.

D. A pharmacist who initiates therapy pursuant to this section:

1. May dispense not more than a thirty-day supply of preexposure prophylaxis.

2. May dispense a complete twenty-eight-day course of postexposure prophylaxis.

3. Shall provide counseling regarding medication adherence, potential side effects and prevention measures.

4. Shall provide the patient with a written referral to a primary care provider or other appropriate health care provider for follow-up care.

5. Shall notify the patient's primary care provider of the services provided if the patient consents to the notification.

E. The statewide written protocol approved by the board shall address, at a minimum, the following:

1. Minimum training requirements for pharmacists who initiate therapy pursuant to this section.

2. Documentation and records retention requirements.

3. Statewide written protocol standards that are consistent with the current guidelines of the United States centers for disease control and prevention or the infectious diseases society of America or another clinically recognized recommendation.

F. For the purposes of this section:

1. "Postexposure prophylaxis" means a medication regimen that is approved by the United States food and drug administration and that is initiated after potential exposure to the human immunodeficiency virus to prevent infection.

2. "Preexposure prophylaxis" means a medication regimen that is approved by the United States food and drug administration to prevent human immunodeficiency virus infection in persons who are at risk.